Brown, Lisle/Cummings’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Brown, Lisle/Cummings's ACAD Position: Q3 2026 in Review
Brown, Lisle/Cummings held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2026 at 500 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #604.
Brown, Lisle/Cummings first reported a position in ACAD in Q2 2024 and has held it in 10 quarters since. The position peaked at $13.4K in Q4 2025. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Brown, Lisle/Cummings held 500 shares of Acadia Pharmaceuticals worth $10.1K as of Q3 2026.
- Brown, Lisle/Cummings left its Acadia Pharmaceuticals share count unchanged in Q3 2026.
- Acadia Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q3 2026, its #604 holding.
- Brown, Lisle/Cummings first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
- Brown, Lisle/Cummings's Acadia Pharmaceuticals position peaked at $13.4K in Q4 2025.
- 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Brown, Lisle/Cummings's 13F filing for Q3 2026, filed 16 Oct 2026.